Collplant Biotechnologies Ltd
NASDAQ:CLGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Collplant Biotechnologies Ltd
Operating Income
Collplant Biotechnologies Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Operating Income
-$11.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Operating Income
$26.2m
|
CAGR 3-Years
80%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Operating Income
-$15m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
0%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Operating Income
-$124.9m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Operating Income
-$11.5m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Operating Income
-$24.9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-1%
|
|
Collplant Biotechnologies Ltd
Glance View
CollPlant Biotechnologies Ltd. is a regenerative medicine company, which engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. The firm provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
See Also
What is Collplant Biotechnologies Ltd's Operating Income?
Operating Income
-11.4m
USD
Based on the financial report for Dec 31, 2025, Collplant Biotechnologies Ltd's Operating Income amounts to -11.4m USD.
What is Collplant Biotechnologies Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-15%
Over the last year, the Operating Income growth was 33%. The average annual Operating Income growth rates for Collplant Biotechnologies Ltd have been 12% over the past three years , -15% over the past five years .
